3DMed aims to improve affordability and large scale accessibility of medical treatment using 3D printed devices. This will be achieved by increasing the TRL of state-of-the-art 3D printing technologies for medical applications and integrating them into a streamlined, fast, cost-effective software platform for use in routine clinical practice. The main objectives are:

• Objective 1 - Streamlining and integration: to streamline the various steps of the 3D manufacturing process and integrate the data flows with pre-planning and post-operatory evaluation;
• Objective 2 - Technology development: advance the TRL of metallic, composite and polymeric 3D printed medical devices;
• Objective 3 - Validation: demonstrate the superior performance and ascertain the clinical benefits of the 3D printed medical devices developed in 3DMed.

• Data transfer protocols to link image acquisition, design and the manufacture (3D printing) of the device;
• Streamlined, fast, cost-effective software platform to connect design and production of 3D printed devices with clinical evaluation (pre- and postop);
• Functionalised, 3D printable polymeric, composites and metallic implants supporting bone reconstruction;
• Six demonstrators validating the superior performance of 3D printed devices;
• Two clinical trials validating the clinical benefits of 3D printed surgical instruments.

The integration of the currently fragmented expertise, technologies and methodologies for 3D printing (3DP) in medical applications requires the joint effort of 'best-in-class' partners and collaborative work across disciplines and borders: TUD is leading worldwide in the field of steerable medical devices; the involved research groups at UG are leading in the field of virtual optimisation and that of biomaterials for 3DP, respectively; ARMINES is well equipped with expertise on 3DP of composites; ULille has top expertise in designing drug release systems and UOx on bioresorbable materials; MTL delivers
preoperative planning solutions, with the unique potential to link with postoperatory evaluation; DORC is market leader in ophthalmic surgical instruments. The consortium also includes innovative companies (AmI, EXO-L, Régnier, 3DLP, OxMestar, Oceanz), as well as clinical observers and clusters throughout the 2Seas area, to catalyse the transfer of results to a critical mass of users.